MDWD

MediWound Ltd.

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.

MediWound Ltd. (MDWD) is rated C+ (2.5/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (B-); its weakest is Growth (D+). The rating has held at C+ for 2 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.5 / 5.0
C+
Value
B-
Factor Score 2.9 / 5.0
Growth
D+
Factor Score 1.8 / 5.0
Profitability
B-
Factor Score 2.9 / 5.0
Momentum
C
Factor Score 2.3 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -5.6
EV / EBITDA -4.9
Rev Growth YoY -45.8%
Gross Margin 15.5%
Price Return 3M -4.3%
Price Return 12M -30.0%
Catalyst Signal 0.00
Market Cap $186.6M
TTM Revenue $11.9M
Price / Sales 15.7
ROE -72.4%

Historical Factor Score Progression

Held C+ for 2 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-13 B- (2.9) D+ (1.8) B- (2.9) C (2.3) C+ (2.6) C+ (2.5)
2026-11-06 B- (2.9) D+ (1.8) B- (2.9) C (2.3) C+ (2.7) C+ (2.5)
2026-10-30 B- (2.9) D+ (1.7) B- (2.9) C (2.4) C+ (2.7) C+ (2.5)
2026-10-23 B- (2.9) D+ (1.7) B- (2.9) C- (2.1) C+ (2.6) C (2.5)
2026-10-16 B- (2.9) D+ (1.7) B- (2.9) C- (2.0) C+ (2.6) C (2.5)
Page 1 of 3